Medicamen Organics Limited has approved the amended Code of Practices and Procedures for Fair Disclosure of Unpublished Price Sensitive Information (UPSI). The Board of Directors approved the code on May 29, 2026, in compliance with Regulation 8(2) of the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015. The amended code is effective from May 29, 2026.

The code establishes a framework for the fair disclosure of events that could impact price discovery for the company's securities. It mandates that UPSI be handled on a need-to-know basis and defines the policy for determining legitimate purposes for sharing such information. The company must ensure timely and adequate disclosure of UPSI to prevent misuse and maintain uniformity in dealing with stakeholders.

Key Provisions

The code designates the Company Secretary & Compliance Officer as the Chief Investor Relations Officer (CIRO). This officer is responsible for disseminating information, determining whether information constitutes UPSI, and responding to market rumours. In the absence of the Company Secretary, the Board may authorise another senior officer to perform these duties.

Structured Digital Database

The Board or the Compliance Officer must maintain a Structured Digital Database (SDD) containing details of shared UPSI. This includes the nature of the information and the names and addresses of individuals who shared or received the information. The SDD must be preserved for at least eight years after the completion of relevant transactions or until the conclusion of any proceedings.

Protection Against Retaliation

The code includes provisions to protect employees who file a Voluntary Information Disclosure Form with SEBI. Such employees shall not be discriminated against, discharged, demoted, suspended, threatened, or harassed for filing the form, testifying in investigations, or aiding SEBI in enforcement actions.

The Audit Committee will review compliance with the code at least once a financial year. The code supersedes the previous version and is subject to review by the Board as necessary.

Medicamen Organics has disclosed a valuation report dated March 12, 2026, issued by M/s Jhamb & Associates, Company Secretaries, in connection with its Extra-Ordinary General Meeting (EGM). The report, prepared by a Registered Valuer in accordance with the SEBI (ICDR) Regulations, 2018, is now available for shareholder review. This disclosure follows previous intimations dated March 17, 2026, and March 27, 2026, regarding the submission of the EGM notice and a subsequent corrigendum.

The EGM is scheduled for May 23, 2026, to seek shareholder approval for various matters specified in the notice. The valuation report provides the necessary financial assessment required for the agenda items being presented. The company has made the document accessible to ensure transparency and informed decision-making by its shareholders.

Key Details of the Disclosure

Shareholders of Medicamen Organics can access the full valuation report on the company’s official website under the corporate announcements section for the financial year 2026-27. The filing was submitted to the National Stock Exchange of India Limited on May 23, 2026, by Divya Sharma, Company Secretary & Compliance Officer.